Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 164

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 164
---
 securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without
notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities.

Stabilization Activities

In accordance with Regulation M under the Exchange
Act, underwriters may engage in over-allotment, stabilizing or short covering transactions or penalty bids in connection with an offering
of our securities. Over-allotment transactions involve sales in excess of the offering size, which create a short position. Stabilizing
transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price.
Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short
positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the
dealer are purchased in a covering transaction to cover short positions. Those activities may cause the price of the securities to be
higher than they would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time.

| 68 |

<div align='center'>Legal
Matters</div>

Certain legal matters in connection with the offering
of securities covered by this prospectus will be passed upon for us by Vinson & Elkins L.L.P. and, with respect to certain matters
of Maryland law, Venable LLP. Additional legal matters may be passed on for us, or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.

<div align='center'>Experts</div>

The consolidated financial statements, and the
related financial statement schedule, of the Company as of December 31, 2023 and 2022, and for each of the three years in the period ended
December 31, 2023, incorporated by reference in this Prospectus by reference to the Company’s annual report on Form 10-K for the
year ended December 31, 2023, and the effectiveness of the Company’s internal control over financial reporting have been audited
by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their reports. Such financial statements
and financial statement schedule have been so incorporated in reliance upon the reports of such firm given upon their authority as experts
in accounting and auditing.

<div align='center'>69

2,000,000 Shares

8.00% Series B Cumulative